Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells

被引:4
|
作者
Komatsu, Tomohiro [1 ,2 ]
Abe, Satomi [1 ]
Nakashima, Shihoko [3 ]
Sasaki, Kei [2 ]
Higaki, Yasuki [1 ,3 ]
Saku, Keijiro [4 ]
Miura, Shin-ichiro [4 ]
Uehara, Yoshinari [1 ,2 ,3 ,4 ]
机构
[1] Fukuoka Univ, Res Inst Phys Act, 8-19-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[2] Fukuoka Univ Hosp, Ctr Prevent Antiaging & Regenerat Med, 7-45-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[3] Fukuoka Univ, Fac Sports & Hlth Sci, 8-19-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[4] Fukuoka Univ Hosp, Dept Cardiol, 7-45-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
关键词
HDL; cholesterol efflux; DPP-4; inhibitor; GLP-1; ABCA1; apoA1; CASSETTE TRANSPORTER A1; TYPE-2; DIABETES-MELLITUS; FUNCTIONAL EXPRESSION; ATHEROSCLEROTIC LESION; SIGNAL-TRANSDUCTION; INSULIN-RESISTANCE; RECEPTOR AGONIST; HDL-CHOLESTEROL; GLP-1; RECEPTOR; FATTY-ACIDS;
D O I
10.3390/biom13020228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesterol efflux is a major atheroprotective function of high-density lipoproteins (HDLs) which removes cholesterol from the foam cells of lipid-rich plaques in Type 2 diabetes. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin phosphate increases plasma glucagon-like peptide-1 (GLP-1) concentrations and is used to treat Type 2 diabetes. GLP-1 plays an important role in regulating insulin secretion and expression via the GLP-1 receptor (GLP-1R), which is expressed in pancreatic islets as well as freshly isolated human monocytes and THP-1 cells. Here, we identified a direct role of GLP-1 and DPP-4 inhibition in HDL function. Cholesterol efflux was measured in cultivated phorbol 12-myristate 13-acetate-treated THP-1 cells radiolabeled with H-3-cholesterol and stimulated with liver X receptor/retinoid X receptor agonists. Contrary to vildagliptin, sitagliptin phosphate together with GLP-1 significantly (p < 0.01) elevated apolipoprotein (apo)A1-mediated cholesterol efflux in a dose-dependent manner. The sitagliptin-induced increase in cholesterol efflux did not occur in the absence of GLP-1. In contrast, adenosine triphosphate-binding cassette transporter A1 (ABCA1) mRNA and protein expressions in the whole cell fraction were not changed by sitagliptin in the presence of GLP-1, although sitagliptin treatment significantly increased ABCA1 protein expression in the membrane fraction. Furthermore, the sitagliptin-induced, elevated efflux in the presence of GLP-1 was significantly decreased by a GLP-1R antagonist, an effect that was not observed with a protein kinase A inhibitor. To our knowledge, the present study reports for the first time that sitagliptin elevates cholesterol efflux in cultivated macrophages and may exert anti-atherosclerotic actions that are independent of improvements in glucose metabolism. Our results suggest that sitagliptin enhances HDL function by inducing a de novo HDL synthesis via cholesterol efflux.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] NEPHROPATHY EVOLUTION IS PREVENTED BY THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR, SITAGLIPTIN, IN A RAT MODEL OF TYPE 2 DIABETES
    Mega, Cristina
    Reis, Flavio
    de Lemos, Edite Teixeira
    Vala, Helena
    Fernandes, Rosa
    Oliveira, Jorge
    Teixeira, Frederico
    Reis, Flavio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 160 - 160
  • [22] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    Raz, I.
    Hanefeld, M.
    Xu, L.
    Caria, C.
    Williams-Herman, D.
    Khatami, H.
    DIABETOLOGIA, 2006, 49 (11) : 2564 - 2571
  • [23] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Aschner, Pablo
    Kipnes, Mark S.
    Lunceford, Jared K.
    Sanchez, Matilde
    Mickel, Carolyn
    Williams-Herman, Debora E.
    DIABETES CARE, 2006, 29 (12) : 2632 - 2637
  • [24] Sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, Can Be Effective Drug for Hepatic Iron Metabolism
    Fukunishi, Shinya
    Asai, Akira
    Tsuda, Yasuhiro
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2016, 150 (04) : S601 - S601
  • [25] Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Indomethacin-Induced Intestinal Mucosal Injury in Rats
    Fujiwara, Kaori
    Inoue, Takuya
    Narabayashi, Ken
    Sakanaka, Taisuke
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Kuramoto, Takanori
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Tokioka, Satoshi
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2013, 144 (05) : S716 - S716
  • [26] The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice
    Yorifuji, Naoki
    Inoue, Takuya
    Iguchi, Munetaka
    Fujiwara, Kaori
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Okada, Toshihiko
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    ONCOLOGY REPORTS, 2016, 35 (02) : 676 - 682
  • [27] The Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Mouse Colon Tumorigenesis in Type 2 Diabetes Mice
    Yorifuji, Naoki
    Inoue, Takuya
    Fujiwara, Kaori
    Iguchi, Munetaka
    Kojima, Yuichi
    Okada, Toshihiko
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S577 - S577
  • [28] Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
    Mistry, Goutam C.
    Maes, Andrea L.
    Lasseter, Kenneth C.
    Davies, Michael J.
    Gottesdiener, Keith M.
    Wagner, John A.
    Herman, Gary A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (05): : 592 - 598
  • [29] Metformin is a GLP-1 secretagogue, not a dipeptidyl peptidase-4 inhibitor
    Roy, R. Sinha
    Bergeron, R.
    Zhu, L.
    He, H.
    Jiang, G.
    Liu, F.
    Lyons, K.
    Pryor, K.
    Yao, J.
    Zhang, B. B.
    Thornberry, N.
    DIABETOLOGIA, 2007, 50 : S284 - S284
  • [30] The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation
    Goncalves, Andreia
    Almeida, Luisa
    Silva, Ana Paula
    Fontes-Ribeiro, Carlos
    Ambrosio, Antonio F.
    Cristovao, Armando
    Fernandes, Rosa
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 102 : 833 - 838